论文信息 - Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial - 字舞流文

Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial

O. Akilov | C. Querfeld | R. Pillai | E. Sievers | M. Irwin | L. D. Johnson | Tina Catalano | Penka S. Petrova | J. Thompson | Matthew H. Taylor | T. Thompson | Bob Uger